ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6

Completed

Conditions: Hepatitis C Virus (HCV)

First Posted Date: 2017-11-14

Last Posted Date: 2021-09-20

Lead Sponsor: AbbVie

Target Recruit Count: 1095

Registration Number: NCT03341871

Locations: 🇯🇵
Abbvie Japan /ID# 161985, Tokyo, Japan

Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

Phase 2

Recruiting

Conditions: Irritable Bowel Syndrome

Interventions: Drug: Placebo
Drug: Eluxadoline

First Posted Date: 2017-11-13

Last Posted Date: 2024-08-09

Lead Sponsor: AbbVie

Target Recruit Count: 95

Registration Number: NCT03339128

Locations: 🇧🇬
MHATSv.Ivan Rilski /ID# 235399, Kozloduy, Bulgaria
🇧🇬
University Hospital Plovdiv /ID# 235450, Plovdiv, Bulgaria
🇨🇦
Duplicate_Edmonton Clinic Health Academy (ECHA) /ID# 234917, Edmonton, Canada

and more 39 locations

Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients

Completed

Conditions: Non-infectious Intermediate, Posterior and Panuveitis

First Posted Date: 2017-11-13

Last Posted Date: 2021-07-19

Lead Sponsor: AbbVie

Target Recruit Count: 158

Registration Number: NCT03339102

Locations: 🇰🇷
Yeungnam University Med Ctr /ID# 201361, Daegu, Daegu Gwang Yeogsi, Korea, Republic of
🇰🇷
Pusan National University Hosp /ID# 202026, Busan, Busan Gwang Yeogsi, Korea, Republic of
🇰🇷
Soon Chun Hyang University Cheonan Hospital /ID# 204551, Cheonan, Chungcheongnamdo, Korea, Republic of

and more 14 locations

Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases

Completed

Conditions: Psoriasis
Ankylosing Spondylitis (AS)
Rheumatoid Arthritis (RA)

First Posted Date: 2017-11-13

Last Posted Date: 2022-07-08

Lead Sponsor: AbbVie

Target Recruit Count: 224

Registration Number: NCT03339089

Locations: 🇨🇳
Sir Run Run Shaw Hospital /ID# 210820, Hangzhou, Zhejiang, China
🇨🇳
The Second Hospital of Jiaxing /ID# 210744, Jiaxing, Zhejiang, China
🇨🇳
Sichuan Provincial orthopedic hospital /ID# 209341, Chengdu, China

and more 7 locations

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Phase 3

Withdrawn

Conditions: Small Cell Lung Cancer

Interventions: Drug: Dexamethasone
Drug: Rovalpituzumab tesirine

First Posted Date: 2017-11-07

Last Posted Date: 2018-12-26

Lead Sponsor: AbbVie

Registration Number: NCT03334487

Locations: 🇺🇸
VA Central California Health C /ID# 170951, Fresno, California, United States
🇺🇸
St. Luke's University Hospital /ID# 171374, Duluth, Minnesota, United States
🇧🇷
Bahia Oncology Center - NOB /ID# 201272, Salvador, Bahia, Brazil

and more 57 locations

A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)

Phase 1

Terminated

Conditions: Breast Cancer

Interventions: Drug: SC-005

First Posted Date: 2017-10-20

Last Posted Date: 2018-12-17

Lead Sponsor: AbbVie

Target Recruit Count: 2

Registration Number: NCT03316794

Locations: 🇺🇸
Memorial Sloan Kettering /ID# 201016, New York, New York, United States
🇺🇸
University of Chicago /ID# 169231, Chicago, Illinois, United States
🇺🇸
Washington University School /ID# 169177, Saint Louis, Missouri, United States

and more 5 locations

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Dexamethasone
Drug: Daratumumab
Drug: Venetoclax
Drug: Bortezomib

First Posted Date: 2017-10-19

Last Posted Date: 2024-06-17

Lead Sponsor: AbbVie

Target Recruit Count: 156

Registration Number: NCT03314181

Locations: 🇦🇺
Eastern Health /ID# 165850, Box Hill, Victoria, Australia
🇨🇦
Cross Cancer Institute /ID# 203114, Edmonton, Alberta, Canada
🇯🇵
Kameda General Hospital /ID# 225246, Kamogawa-shi, Chiba, Japan

and more 37 locations

A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors Cancer

Interventions: Drug: ABBV-399

First Posted Date: 2017-10-17

Last Posted Date: 2019-03-14

Lead Sponsor: AbbVie

Target Recruit Count: 9

Registration Number: NCT03311477

Locations: 🇯🇵
National Cancer Center Hospital /ID# 166939, Chuo-ku, Tokyo, Japan
🇯🇵
Shizuoka Cancer Center /ID# 166940, Sunto-gun, Shizuoka, Japan

A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan

Phase 3

Completed

Conditions: Pyoderma Gangrenosum

Interventions: Drug: adalimumab

First Posted Date: 2017-10-17

Last Posted Date: 2021-03-09

Lead Sponsor: AbbVie

Target Recruit Count: 22

Registration Number: NCT03311464

Locations: 🇯🇵
Nagoya City University Hospital /ID# 164510, Nagoya-shi, Aichi, Japan
🇯🇵
Juntendo University Urayasu Hospital /ID# 164422, Urayasu Shi, Chiba, Japan
🇯🇵
Fukuoka University Hospital /ID# 164416, Fukuoka-shi, Fukuoka, Japan

and more 17 locations

Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice

Completed

Conditions: Chronic Lymphocytic Leukemia

First Posted Date: 2017-10-16

Last Posted Date: 2023-03-30

Lead Sponsor: AbbVie

Target Recruit Count: 93

Registration Number: NCT03310190

Locations: 🇨🇦
The Moncton Hospital /ID# 166043, Moncton, New Brunswick, Canada
🇨🇦
Jack Ady Cancer Centre /ID# 217491, Lethbridge, Alberta, Canada
🇨🇦
Jewish General Hospital /ID# 166418, Montreal, Quebec, Canada

and more 10 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy